Yeungnam University   Report issue

Academic/Hospital Phase 3 Phase 4
Founded: Gyeongsan Korea, Republic of (1947)

Organization Overview

First Clinical Trial
2006
NCT00386529
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Department of Anesthesiology and Pain Medicine, College of medicine, Yeungnam University, Daemyung-Dong, Nam-Gu, Daegu, Republic of Korea | Min Cheol Chang | Yeungnam University College of Medicine | Yeungnam University College of Medicine , Daegu, Korea | Yeungnam University Hospital | Yeungnam University Hospital of Korea | Yeungnam Univ. Medical Center

Active Ingredients

Drugs in Phase 4 Trials (16)

5,7-dihydroxy-3',4',6-trimethoxyflavone (2 trials)

acetylsalicylic acid (aspirin) (2 trials)

adefovir dipivoxil (hepsera) (1 trial)

aflibercept (zaltrap) (1 trial)

amlodipine (norvasc) (2 trials)

bevacizumab (avastin) (2 trials)

dexamethasone (2 trials)

hifenac (1 trial)

lamivudine (epivir) (1 trial)

misoprostol (cytotec) (1 trial)

pitavastatin (livalo) (1 trial)

ranibizumab (lucentis) (1 trial)

silodosin (rapaflo) (2 trials)

telmisartan (micardis) (1 trial)

tenofovir (viread) (1 trial)

urea (3 trials)

Drugs in Phase 3 Trials (21)

allogeneic adipose derived mesenchymal stem cell (2 trials)

avanafil (stendra) (1 trial)

brolucizumab-dbll (Beovu) (1 trial)

candesartan (atacand) (1 trial)

capecitabine (xeloda) (1 trial)

cellulose (1 trial)

cisplatin (platinol) (1 trial)

fimasartan (kanarb) (3 trials)

gimeracil (3 trials)

lactobacillus sakei (1 trial)

levodropropizine (1 trial)

losartan (cozaar) (1 trial)

moxifloxacin (avelox) (1 trial)

oteracil (3 trials)

oxaliplatin (eloxatin) (1 trial)

phenylephrine (Prefrin) (1 trial)

s-1 (2 trials)

tegafur (3 trials)

theobromine (1 trial)

udenafil (2 trials)

zabofloxacin (1 trial)

Drugs in Other Trials (13)

bupivacaine (Exparel) (1 trial)

dexmedetomidine (precedex) (2 trials)

epinephrine (levophed) (1 trial)

fentanyl (Innovar) (2 trials)

ketorolac (acuvail) (1 trial)

midazolam (versed) (1 trial)

oxycodone (oxycontin) (1 trial)

palonosetron (aloxi) (1 trial)

propofol (diprivan) (2 trials)

remifentanil (ultiva) (7 trials)

sevoflurane (ultane) (5 trials)

sodium chloride (1 trial)

triamcinolone (kenalog) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Arthritis (Phase 3)

Bronchitis (Phase 3)

Colorectal Neoplasms (Phase 3)

Coronary Artery Disease (Phase 4)

Dermatitis (Phase 3)

Dermatitis, Atopic (Phase 3)

Diabetes Mellitus (Phase 4)

Diabetic Retinopathy (Phase 4)

Eczema (Phase 3)

Edema (Phase 4)

Erectile Dysfunction (Phase 3)

Essential Hypertension (Phase 3)

Gastritis (Phase 3)

Hepatitis (Phase 4)

Hepatitis A (Phase 4)

Hepatitis B (Phase 4)

Hepatitis B, Chronic (Phase 4)

Hepatitis, Chronic (Phase 4)

Hyperlipidemias (Phase 4)

Hyperlipoproteinemias (Phase 4)

Hyperplasia (Phase 4)

Hypertension (Phase 4)

Lung Diseases (Phase 3)

Lung Diseases, Obstructive (Phase 3)

Macular Edema (Phase 4)

Osteoarthritis (Phase 3)

Osteoarthritis, Knee (Phase 3)

Prostatic Hyperplasia (Phase 4)

Pulmonary Disease, Chronic Obstructive (Phase 3)

Retinal Vein Occlusion (Phase 4)

Stomach Neoplasms (Phase 3)

Stroke (Phase 3)

Urinary Bladder, Neurogenic (Phase 4)

Wounds and Injuries (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 47
  • # of Trial APIs: 50